Higher-Dose eye injection may help wet AMD patients who Didn't respond to standard treatments
NCT ID NCT06683950
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests whether switching to a higher dose (8mg) of aflibercept can help people with wet age-related macular degeneration (AMD) who have not responded well to standard treatments like faricimab or the usual 2mg dose of aflibercept. Participants receive up to three injections of the higher dose, and doctors monitor changes in retinal fluid and vision. The goal is to see if this approach can better control the disease with fewer injections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aflibercept 8mg injection into the eye
- What this could lead to
- If successful, this could offer a more effective treatment option for people with wet AMD who have not responded well to existing therapies, potentially reducing the number of injections needed.
- What could go wrong
- This is a small, early-phase study with only 35 participants, so results may not apply to everyone. The higher dose may also carry unknown risks or side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (ARMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kim's Eye Hospital
Seoul, Seoul, 150-034, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Eye injection aims to tame leading causes of blindness
- New eye drug aims to save sight in wet AMD
- Withdrawn study sought better way to time eye injections
- Cheaper eye drug could save millions in AMD treatment costs
- New eye injection shows promise for wet AMD in everyday practice
- New eye drug aims to offer cheaper option for blinding disease